CureSHANK is a research advocacy organization expediting life-changing therapies for Phelan-McDermid syndrome (PMS), a highly disabling neurodevelopmental disorder caused by pathogenic changes to the SHANK3 gene.

We are committed to helping improve speed and efficiency in the field, so that PMS treatments get from lab to loved ones more quickly. We believe that together we can build a better future for families dealing with Phelan-McDermid syndrome and other SHANK-related neurodevelopmental disorders.

CureSHANK’s strategic priorities are projects that help to bridge the “translational research gap” between basic science and successful clinical trials. We identify and fund projects related to drug discovery and design, pre-clinical development, and early phase clinical trials.